157 related articles for article (PubMed ID: 34717001)
1. Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature.
Gobbi MF; Eduardo FP; Bezinelli LM; de Carvalho DLC; Monção do Vale SK; Corrêa L
Spec Care Dentist; 2022 May; 42(3):286-293. PubMed ID: 34717001
[TBL] [Abstract][Full Text] [Related]
2. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
3. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Fujimura S; Taguchi A; Shoji K
Auris Nasus Larynx; 2020 Apr; 47(2):309-313. PubMed ID: 31235078
[TBL] [Abstract][Full Text] [Related]
4. A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab.
Galliazzo S; Morando F; Sartorato P; Bortolin M; De Menis E
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):363-366. PubMed ID: 34238203
[TBL] [Abstract][Full Text] [Related]
5. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
Fu S; Wang T; Xu F
J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract][Full Text] [Related]
7. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced adrenalitis.
Iqbal I; Khan MAA; Ullah W; Nabwani D
BMJ Case Rep; 2019 Dec; 12(11):. PubMed ID: 31791986
[TBL] [Abstract][Full Text] [Related]
9. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced oral lichenoid reaction during nivolumab therapy.
Enomoto Y; Nakatani H; Kondo S; Kasai T; Tsuchiya Y
Int J Oral Maxillofac Surg; 2019 Apr; 48(4):488-491. PubMed ID: 30170775
[TBL] [Abstract][Full Text] [Related]
11. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
13. Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
Hisamatsu Y; Morinaga R; Watanabe E; Ohtani S; Shirao K
Am J Case Rep; 2020 Feb; 21():e920809. PubMed ID: 32018275
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
15. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
[TBL] [Abstract][Full Text] [Related]
16. Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.
Hobbs KB; Yackzan S
Clin J Oncol Nurs; 2020 Jun; 24(3):240-243. PubMed ID: 32441673
[TBL] [Abstract][Full Text] [Related]
17. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
19. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
[TBL] [Abstract][Full Text] [Related]
20. Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event.
Deligiorgi MV; Trafalis DT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107050. PubMed ID: 33069924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
